title: Osteogenic protein-1 overcomes inhibition of fracture healing in the diabetic rat: a pilot study.
abstract: Type I diabetes mellitus inhibits fracture healing and leads to an increase in complications. As a pilot study, we used a closed fracture model in the diabetic rat to address the question of whether osteogenic protein-1 (OP-1) in a collagen carrier can overcome this inhibition by increasing the area of the newly mineralized callus and femoral torque to failure compared with diabetic animals with fractures treated without OP-1. Diabetes was created in 54 rats by injection of streptozotocin. After 2 weeks, a closed femur fracture was created using a drop-weight impaction device. Each fracture site was immediately opened and treated with or without 25 microg OP-1 in a collagen carrier. Animals were euthanized after 2 or 4 weeks. Fracture healing was assessed by callus area from high-resolution radiographs, callus strength from torsional failure testing, and undecalcified histologic analysis. The area of newly mineralized callus was greater in diabetic animals treated with 25 microg OP-1/carrier compared with diabetic animals with untreated fractures and with fractures treated with carrier alone. This increase in callus area did not translate into an equivalent increase in torque to failure. Osteogenic protein-1 showed some evidence of overcoming the inhibition of fracture healing in the diabetic rat.
authors.affiliation: Orthopaedic Biomechanics Laboratory, Midwest Orthopaedic Research Foundation, Minneapolis, MN, USA. kidde001@umn.edu
authors.forename: Louis S
authors.initials: LS
authors.lastname: Kidder
authors.forename: Xinqian
authors.initials: X
authors.lastname: Chen
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Schmidt
authors.forename: William D
authors.initials: WD
authors.lastname: Lew
mesh_terms: D000818:Animals; D001696:Biomechanical Phenomena; D055419:Bone Morphogenetic Protein 7 / Q000008:administration & dosage*; D002146:Bony Callus / Q000187:drug effects / Q000503:physiopathology; D002113:Calcification, Physiologic / Q000187:drug effects; D024042:Collagen Type I; D003921:Diabetes Mellitus, Experimental / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology; D003922:Diabetes Mellitus, Type 1 / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology; D004337:Drug Carriers; D005264:Femoral Fractures / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D017102:Fracture Healing / Q000187:drug effects*; D005596:Fractures, Closed / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D010865:Pilot Projects; D011859:Radiography; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D019415:Torque
chemical_list: D055419:Bone Morphogenetic Protein 7; D024042:Collagen Type I; D004337:Drug Carriers